Input |
|
Results |
||
α |
|
|
|
|
β |
|
|
|
|
Allowable difference |
|
|
N |
|
Population variance |
|
|
|
|
δ |
|
|
|
|
Note:
Variables |
Descriptions |
α |
One-sided significance level |
1-β |
Power of the test |
Allowable difference |
Acceptable difference between sample mean and known or population mean (µ-µ0) |
Population variance |
Population variance |
δ |
Equivalence limit |
N |
Sample size |
Help
Aids Top
Application: The test drug is determined to be equivalent to a gold standard on average if the null hypothesis is rejected at significance level α. The following hypotheses are usually considered:
Procedure:
a) value of α, the probability of type I error
b) value of β, the probability of type II error
c)
value of allowable difference
d) value of Population variance
e) value of δ>0, the equivalence limit.
Formula:
(*)
Notations:
α: The
probability of type I error (significance level) is the probability of rejecting the true null
hypothesis.
β: The
probability of type II error (1 – power of the test) is the probability of
failing to reject the false null hypothesis.
δ: The largest change from the reference value (baseline) that is considered to be trivial.
μ – μ0: The value of allowable difference is the difference value between true mean and reference mean (constant value).
Examples
Example 1: Concerning
the effect of a test drug on body weight change in terms of body mass index
(BMI) before and after the treatment, we consider that a less than 5% change in
BMI from pre-treatment is not safety concern for the indication of the disease
under study. Thus, δ=5% as the
equivalence limit and to demonstrate safety by testing equivalence in mean BMI
between pre-treatment and post-treatment of the test drug. Now, if true BMI
difference is 0 (μ–μ0=0)
and the population variance is 0.01, by (*) with α=0.05, we required the sample
size of N=35 to achieve an 80% power (β=0.2).
Reference: Chow, Shao and Wang, Sample Size Calculations In
Clinical Research,